The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is a common, heterogeneous malignancy in women.
• Signal transducer and activator of transcription 3 (Stat3) is frequently overexpressed and hyperactivated in breast tumors, making it a potential therapeutic target.
• Developing novel Stat3 inhibitors is crucial for advancing breast cancer treatment strategies.

Purpose of the Study:

• To evaluate the anti-cancer activities of a novel Stat3 inhibitor, Statmp-151.
• To assess the efficacy of Statmp-151 in various breast cancer cell lines and a murine model.
• To investigate the molecular mechanisms underlying Statmp-151's effects on cancer cells.

Main Methods:

• In vitro studies using MCF-7, MDA-MB-231, and 4T1 breast cancer cell lines.
• Assays included proliferation, Stat3 phosphorylation, flow cytometry (mitochondrial membrane potential, ROS production), and matrix metalloproteinase (MMP2, MMP9) analysis.
• In vivo efficacy was tested in a 4T1 tumor-bearing mouse model with intraperitoneal injections of Statmp-151.

Main Results:

• Statmp-151 demonstrated dose- and time-dependent inhibition of breast cancer cell proliferation.
• The inhibitor suppressed Stat3 phosphorylation and affected mitochondrial membrane potential and reactive oxygen species (ROS) production.
• Statmp-151 reduced cancer cell migration by inhibiting MMP2 and MMP9, and significantly suppressed tumor growth in mice without apparent toxicity.

Conclusions:

• Statmp-151 exhibits significant anti-cancer properties in vitro and in vivo.
• The novel compound effectively targets Stat3 signaling in breast cancer cells.
• Statmp-151 represents a promising therapeutic candidate for breast cancer treatment.